Voices
Paolo Ciracì: Results from the Phase 3 KRYSTAL-10 Trial
Paolo Ciracì

Paolo Ciracì: Results from the Phase 3 KRYSTAL-10 Trial

Paolo Ciracì, Medical Oncology Resident at the University Hospital of Pisa, shared a post on X:

“Results from the phase 3 KRYSTAL-10 trial (2L KRAS G12C-mut mCRC):

  • adagrasib + cetuximab did not meet its dual primary endpoints of PFS and OS vs chemo ± anti-VEGF/R.
  • ORR was numerically higher (47% vs 16%).”

Paolo Ciracì: Results from the Phase 3 KRYSTAL-10 Trial

More posts featuring ChemoTherapy on OncoDaily.

Adagrasib Amgen Bristol Myers Squibb cancer Cancer research cetuximab clinical trials colorectal cancer Eli Lilly ESMO GI 2026 Gastrointestinal Oncology KRAS G12C KRAS G12C mutation KRYSTAL-10 mCRC Metastatic colorectal cancer microsatellite stable Mirati Therapeutics MSS objective response rate OncoDaily Oncology oncology drug development ORR OS overall survival Paolo Ciracì PFS Phase 3 Trial Precision Oncology progression-free survival targeted therapy